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Introduction
The concept of 'junk DNA' arose from an observation: that DNA content is poorly correlated with the complexity of an organism; for example, the onion genome is approximately five times greater than human. To resolve this paradox, geneticists suggested that most DNA has no biological purpose and could be considered 'junk'. This dogma has been challenged recently by studies such as the ENCODE project, which estimated that up to 80% of the genome has function [1, 2] ; although this has been considered by some to be an over-estimate [3, 4] . ENCODE has, nevertheless, focussed attention on possible functions for 'junk DNA'-including work on repeat elements, such as minisatellites.
Chromosome 19 is unusually rich in repetitive DNA and one repeat element-the 36-38 bp minisatellite sequence, MSR1-has been reported to be specific to this chromosome [5, 6] . It was shown that copy number variation (CNV) of MSR1 regulates gene expression, with CNV of MSR1 repeats located upstream to the PRPF31 promoter affecting transcription of the downstream gene [7] . A cluster of MSR1 elements was identified within the murine troponin I (TnIc) promoter, and deletion alters Tnlc expression [8, 9] . Furthermore, MSR1 sequence might regulate expression of an aberrant KLK4 sense-antisense chimera transcript in prostate cancer cells [10] .
The emerging influence of CNV of MSR1 on gene expression implicates a role in oncogenesis and, in this work, the regulatory potential of MSR1 repeats was explored, with focus on the oncogenic kallikrein locus.
Methods

Bioinformatic methods
The MSR1 consensus sequence was identified from Repbase [11] . MSR1 family membership and sequence boundaries were determined by RepeatMasker, using the consensus sequence of the family. A hidden Markov model (HMM) profile was constructed using multiple sequence alignment and an extensive whole genome search for profile HMM was carried out using nHMMER with strict profile threshold (E ¼ 1 Â 10 À8 ) [12] . The analysis followed the standard pipeline for transposon-related repeat families [13] .
RepeatMasker annotations track for MSR1 family was probed for intersection with several regulatory tracks of ENCODE using Table Browser tool of UCSC genome browser (http://genome.ucsc.edu/) [14] . The regulatory data from seven cell lines assayed in ENCODE was analysed (GM12878, K562, H1 human embryonic stem cells, HSMM, HUVEC, NHEK and NHLF). These cell lines were used as there is full, robust data of H3K marks and other regulatory signals.
MSR1 repeats were probed in silico for their putative effect on genes using three models of gene regulation: (i) Basal-plus-extension; (ii) Twonearest-gene and (iii) Single-nearest-gene (bioinformatic pipelines available on request).
The list of genes that were possibly regulated by MSR1 repeat elements was analysed to detect functional clustering of protein domain (InterPro domains, https://www.ebi.ac.uk/interpro/), Molecular Signature Database (MSigDB, http://software.broadinstitute.org/gsea/msigdb/index.jsp), DAVID gene ontology (https://david.ncifcrf.gov/) and cis-regulatory functional domains (GREAT software; http://bejerano.stanford.edu/help/display/ GREAT/) [15] .
Analysis of gene dysregulation in malignancy and the kallikrein locus
Gene dysregulation data from 20 malignancies was obtained from COSMIC database (http://cancer.sanger.ac.uk/cosmic). Data for CNV of MSR1 at the kallikrein locus were obtained through UCSC genome browser (https://genome.ucsc.edu). Specifically, data were analysed for intersection of MSR1 sequence on the RepeatMasker track, with CNV data on the DGV structural variation track.
Vector preparation and dual-luciferase reporter assay
Non-labelled PCR product was amplified using template DNA from a control individual. A modified pGL3-basic vector (Promega) was used, containing a basic thymidine kinase promoter (pTK), and the fragments were cloned upstream to the TK sequence. Dual-luciferase reporter assay was carried out in MCF7, RPE-1 cells and HeLa cells by transient transfection, as previously described [7] .
Patient selection
Breast cancer. Peripheral blood DNA was obtained from Tayside Biorepository, these being samples from White-British patients with a diagnosis of primary breast cancer (BrCa) without family history suggestive of familial inheritance. The control samples were women from the same ethnic population with no history of BrCa, obtained from Generation Scotland 3D resource or ECACC control panels [16] . Written, informed consent was obtained from all individuals, and local ethics approval was gained from the NHS Research Ethics Committee for Scotland A (REC reference number: 06/MRE00/105).
Prostate cancer. A total of 905 prostate cancer (PrCa) patients were genotyped. From these, 600 patients were recruited via collaborations with The Cancer Council Queensland (ProsCan study) and 305 samples were provided by patients who donated blood to the QLD node of the Australian Prostate Cancer BioResource (APCB) as detailed previously [17, 18] . From the 842 healthy controls analysed, 334 were recruited through the Australian Red Cross Blood Services and 508 were enrolled through the Electoral Roll, where age-and postal code-matched patients to the ProsCan study were selected [17] . All methods were carried out in accordance with relevant guidelines and regulations, and all experimental protocols were approved by QUT's Human Ethics Committee (Ethics' Approval number: 1000001171), the Australian Red Cross Services (Ethics' Approval number: 2004#17) and Cancer Council Queensland (Ethics' Approval number: 3629 H). Only patients who provided informed written consent were included in the study.
Analysis of patient genotype
Breast cancer. In total, 633 patients with non-familial BrCa and 650 controls underwent analysis. PCR was carried out using an FAM-labelled forward primer (5 0 FAM-GAAGCTGGATTGAGGAAACG) and an unlabelled reverse primer (GTGCCTCCGGTCTTGAGTAG). PCR products underwent a standard genotyping reaction and were analysed on ABI 3130x. Data were analysed using Data Collection v30 and Gene Mapper v4.1.
Prostate cancer. A touchdown PCR was optimised using the GoTaq Green Master Mix (Promega, Sydney, Australia). The first 10 cycles of the PCR used an annealing temperature of 63 C while the remaining 30 cycles were carried out at 62 C. The rest of the conditions for both series were identical, with an initial denaturation temperature of 95 C for 30 s and a final elongation temperature of 72 C for 45 s. A subsequent 10 min at 72 C finalised the protocol. The primers used were the same as for breast cancer samples. MSR1 copy number was assessed on agarose gels using a sizing ladder.
Statistical analysis
Breast cancer. Due to small sample size, v 2 testing was applied to compare the risk of disease in those carrying only the major allele (homozygous 11 copies), as compared with those carrying minor alleles (8, 9 or 10 copies). The odds ratio (OR) was estimated using conditional maximum likelihood estimate. Dose-response analysis was carried out by an Extended Mantel-Haenszel v 2 for linear trend. Sub-type analysis was carried out for age of onset and histological sub-type. Statistical analysis was carried out using OpenEpi v3.03 (www.openepi.com).
Prostate cancer. Association of MSR1 was analysed for prostate cancer risk using univariate binary logistic regression (IBM SPSS Statistics; 23.0), where the dependant variable is the case-control status. A P < 0.05 was considered significant, and OR and 95% confidence interval (CI) are shown. For genotype association analysis, the most common allele, homozygous 11/11, was used as a reference. Random sampling with replacement tests has been carried out using the bootstrapping analysis (IBM SPSS Statistics 23.0) using a seed value of 1000 samples 1 000 000 times. To confirm the results were not age-related, both the univariate binary logistic regression and the bootstrapping were age-corrected. The allele/genotype was used as the categorical value and the age was the categorical co-variate. The prostate cancer/control status was the unique dependant variable.
Results
MSR1 repeat elements are distributed across the genome, with highest density on chromosome 19q
The non-redundant (canonical) MSR1 sequence was found to have 978 hits across the human genome ( Figure 1A and were integrated into all eight analytic sub-groups, thus highlighting generality of these regulatory signals. Relative position (C) and absolute distance (D) to gene TSS for genes detected by 'basal-plus-extension' methods; relative position (E) and absolute distance (F) to gene TSS for genes detected by 'two-nearest-genes' method; and relative position (G) and absolute distance (H) to gene TSS for genes detected by 'single-nearest-gene' method.
supplementary Table S1 and Figure S1A -C, available at Annals of Oncology online). Additionally, there were >2000 further instances of degenerate sequence genome-wide (supplementary Figure S1D , available at Annals of Oncology online). The canonical HMM sequence had the highest level of conservation, and was observed most frequently (>550 hits) on chromosome 19 ( Figure 1A ). There were also a reasonable number of occurrences on chromosome 7 (110 occurrences) and chromosome 1 (44 occurrences). All other chromosomes had a small number of occurrences (<30), but MSR1 was not evident on the mitochondrial genome (supplementary Table S1 , available at Annals of Oncology online).
MSR1 repeats coincide with genomic markers of gene regulation
To investigate if MSR1 repeats are a global regulator of transcription, it was considered whether the elements coincided with genomic markers of regulation ( Figure 1B ). It was found that 70% of MSR1 elements are located within open chromatin and, furthermore, a large proportion of MSR1 repeats were associated with H3K27ac (70%), H3K4me1 (83%) and/or H3K4me3 (85%). MSR1s were less commonly associated with DNaseI hypersensitivity sites, transcription factor binding sites, DNA methylation marks or FAIRE signal.
Serine-protease genes and ion channel genes are putatively regulated by MSR1 elements
Having identified that the majority of MSR1 sequence coincided with markers of gene regulation, it was considered important to study which genes might be regulated by the repeat, and to see whether these genes shared any common features.
Only MSR1 repeats with highest fidelity were studied at this time, as it was felt that these were most likely to be functional. This highlighted 227 genes, mainly on chromosome 19, which are prime candidates for regulation by MSR1 repeats (supplementary Figure S2 , available at Annals of Oncology online). The genetic distance between the MSR1 repeat element and transcription start sites (TSSs) of putatively regulated genes was then studied, showing that the vast majority of MSR1 elements were located within 50 kB of TSS, with a significant proportion located very close to the gene TSS (<5 kB) ( Figure 1C-H) . By the basal-plusextension method, 41.0% were located between 0 and 5 kB of TSS and 52.9% were located at a distance of 5-50 kB; by the twonearest-gene method, the respective figures were 31.8% and 60.6%, respectively and for the single-nearest-gene method, 58.9% and 40.5%.
Gene ontology analysis of the functional clustering of genes putatively regulated by MSR1 elements showed enrichment for a number of molecular functions (supplementary Table S2 , available at Annals of Oncology online). In particular, MSR1-containing genes were strongly enriched for serine peptidase activity (P < 4.8 Â 10
À7
) and ion channel activity (P ¼ 2.7 Â 10 À4 ) ( Figure 2A ). This was confirmed on analysis of InterPro signatures, which showed strong enrichment for peptidase domains (P ¼ 1.5 Â 10
À9
) and voltage-gated ion channels (P ¼ 3.2 Â 10 À3 ) ( Figure 2B ).
Genes containing MSR1 clusters are frequently dysregulated in cancer
The 227 genes that were identified as candidates for regulation by MSR1 repeats were analysed for dysregulation in 20 common malignancies. Gene expression data in malignancy was available for all but 13 of the genes. This showed that all the analysed genes putatively controlled by MSR1 were over-expressed in at least 5% of some cancer types, and 50 of the genes were dysregulated in a large proportion of at least one tumour type (!15%) (Figure 3 and  supplementary Table S3 , available at Annals of Oncology online). Under-expression of genes regulated by MSR1 was far less common, with only 78 of the genes being reported as under-expressed, and only 3 genes being reported as frequently under-expressed (supplementary Table S4 , available at Annals of Oncology online).
The kallikreins are a family of serine-proteases encoded by a series of tandem-array genes located at chromosome 19q13.4-totalling 15 genes and one pseudo-gene ( Figure 4A ). Gene ontology analysis had indicated a strong functional clustering for serine-peptidases, due to functional clustering of 15 genes (CAPN1, HPN, KLK1, KLK10, KLK13, KLK14, KLK15, KLK2, KLK3, KLK4, KLK6, KLK7, KLK8, KLK9 and PSENEN). Further analysis of the kallikrein locus mapped a large number of MSR1 clusters ( Table 1) . Analysis of deep-sequencing data showed that at least six of the clusters harboured CNV in a control population, these clusters lying closest to KLK4, KLK7, KLK14 and KLK15.
CNV of the KLK14 MSR1 cluster alters gene transcription in vitro
A cluster of MSR1 repeats located within the 3 0 UTR of KLK14 was selected for further study ( Figure 4B ). This cluster was chosen because it demonstrated CNV in previously published population data and KLK14 has associations with breast and prostate cancer.
The cluster of interest was amplified from control individuals of Northern European descent, demonstrating four alleles (8, 9, 10 or 11 copies). The 11-copy allele was the major allele, but 9-copy was reasonably frequent (MAF ¼ 13.3%). The 8-and 10-copy alleles existed at <1% frequency and were considered rare variants.
The two common alleles (11-or 9-MSR1 copies) were cloned upstream to a basic promoter in both forward and reverse strand orientation, and dual luciferase reporter activity was tested in MCF7, HeLa and RPE-1 cell lines (Figure 4C-E and supplementary Tables S5 and S6 , available at Annals of Oncology online). It was demonstrated that the presence of MSR1 elements enhanced basal transcription, but that the 9-copy allele had a significantly greater effect on reporter activity than the 11-copy allele.
In the forward strand orientation, the 9-copy allele (KLK14-9) had 4.9-to 9.1-fold induction over pTK; similarly, in the reverse strand orientation, KLK14-9 had 5.0-to 6.9-fold induction over pTK. In contrast, the 11-copy allele (KLK14-11) had a lesser enhancing effect on transcription, with 2.5-to 5.5-fold induction (forward) or 3.0-to 3.5-fold induction (reverse). The difference between 9-copy and 11-copy alleles was statistically significant for both forward and reverse strand orientations in all three cell lines (P < 1 Â 10 -5 ). It can, therefore, be considered that the observed polymorphism causes a functional change and that the 9-copy allele drives relatively higher expression of KLK14 than the 11-copy allele.
CNV of MSR1 is a major risk for non-familial breast cancer
As a functional role of the MSR1 CNV was demonstrated, and KLK14 dysregulation is associated with BrCa, a case-control analysis was carried out for non-familial disease (supplementary Table S7 , available at Annals of Oncology online). The risk of developing BrCa was studied by calculating the dose response to the 9-copy KLK14 allele; that is, the risk of carrying heterozygous exposure or homozygous exposure, as compared with baseline exposure of no rare alleles (11, 11 homozygotes) . 
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LGALS7 TARM1   TEAD2   TEX101   TFPT   TIMM50   TMC4   TMEM143   TMEM145   TMEM150B   TMEM190   TMEM238   TMEM86B   TNNI3   TNNT1   TOMM40   TP73   TRPM4   TSKS   TTYH1   TULP2   U2AF1L4 There is a strong stratified association between the number of 9-copy alleles and the relative risk of BrCa (Table 2) . Heterozygotes (9, 11) have 1.21-time higher risk than 11-copy homozygotes, while 9-copy homozygotes have a 3.51-time higher risk (MH v 2 ¼ 8.25; P ¼ 0.004). The observed effect was strongest for individuals with earlyonset BrCa (less than 50 years), with heterozygous carriers having 1.65-time higher risk and, remarkably, homozygous carriers having 5.34-time increased risk (MH v 2 ¼ 10.71; P ¼ 0.001). The trend did not reach statistical significance for patients with onset of disease at 50 years and older (MH v 2 ¼ 2.98; P ¼ 0.08). The association was significant for the estrogen receptor (ER) positive subtype, with 1.22-to 3.42-time increased risk in heterozygous and homozygous carriers, respectively (MH v 2 ¼ 5.62; P ¼ 0.02). The association between the 9-copy allele and ER-negative histological subtype did not reach significance.
There were insufficient individuals carrying the rare alleles (8-or 10-copy) and so it was not possible to perform a dose-
Centromeric response analysis. Instead, v 2 analysis was carried out; this did not show significant association between the rare alleles and risk of BrCa (P >0.05).
The association was replicated by re-analysis of previously published data [19] . Although only a small number of cases and controls were available (24 of each group), analysis of doseresponse replicated the association of the 9-copy allele with nonfamilial BrCa in a second, independent population (P ¼0.03, Table 2 ).
CNV of MSR1 is a major risk for prostate cancer
The association between MSR1 CNV at the KLK14 locus and PrCa was then assayed in an Australian case-control cohort, as a further replication and validation of the association between MSR1 CNV and malignancy. The two most common alleles were the 9 and 11 repeats, the 11-copy being the major allele (11-copy allele frequency ¼ 79.6%; 9-copy allele frequency ¼ 17.1%). Interestingly, a greater variety of rare alleles were observed in the Australian population: 6 copies (0.2%), 8 copies (1.3%), 10 copies (1.2%), 12 copies (0.4%) and 13 copies (0.1%) (supplementary Table S8 , available at Annals of Oncology online).
The 9-copy allele was shown to be significantly associated with prostate cancer risk at allele level (OR ¼ 1.3, CI ¼ 1.1-1.6, P ¼ 0.001) and genotype level (OR ¼ 1.3, CI ¼ 1.04-1.6, P ¼ 0.001). The results were age independent and confirmed by bootstrapping (Tables 2 and 3 ). The major 11-copy allele was associated with a protective effect (OR ¼ 0.65, CI ¼ 0.5-0.9, P ¼ 0.025) and the results were also age-independent and confirmed by bootstrapping (Table 3) .
Discussion
The ENCODE project predicted that many 'junk DNA' sequences, including repetitive elements, would have a molecular function. MSR1 is a minisatellite sequence that was previously considered chromosome 19 specific [6] . Recently, MSR1 repeat elements were implicated in regulation of gene expression-with CNV of MSR1 at the PRPF31 locus modulating expression of the upstream gene [7] .
In this work, bioinformatic methods were used to establish the distribution of MSR1s within the human genome, to explore whether MSR1 acted as a global regulator of gene expression, and to investigate how regulation of gene expression by MSR1 influences malignancy.
First, this work has shown that the MSR1 sequence is not exclusively located on chromosome 19-but is found on all chromosomes, except the mitochondrial genome. Most MSR1 repeat elements were found to be located close to gene TSS-this being suggestive of a role in short-range regulation. Furthermore, more than 70% of MSR1 elements intersect with H3K marks. H3K marks tend to be associated with short-range enhancers; as opposed to FAIRE signal, which is associated with long-range elements and with which there was little intersection. This is supportive of previously published work that looked at the putative mechanism of action of MSR1 [7] . This work showed that spatial relation of the MSR1 cluster to the promoter sequence was Table 1 . Location and orientation of MSR1 clusters within the kallikrein locus, with the nearest gene and the copy number variants identified in a previously published database of whole genome deep-sequencing in a control population critical for the effect of CNV and that the element did not bind transcription factors nor was it a target for epigenetic regulation [7] . It was proposed, therefore, that 3D DNA conformational change (e.g. DNA looping) was the mechanism by which MSR1 affected gene transcription. Next, gene ontology and functional clustering analyses showed that MSR1 sequence chiefly regulated genes with ion-channel and serine-peptidase function, including the kallikrein locus. Dysregulation of protease activity is one of the key events implicated in tumour growth and progression, both at primary and metastatic disease sites [20] . Our analysis found that serineprotease genes were strongly enriched for MSR1 elements (P < 4.80 Â 10
À7
) due to clustering in the kallikrein locus. Dysregulation of kallikrein genes has been implicated in several malignancies; particularly endocrine cancers (prostate, breast and ovarian) but also adenocarcinoma of the colon, lung and pancreas, neuroendocrine tumours, and acute lymphoblastic leukaemia [21, 22] . It was found that at least four kallikrein genes harboured MSR1 CNV in a normal population: KLK4, KLK7, KLK14 and KLK15. However, the structural variation data available for analysis was from a small sample of South Asian Malay individuals and is, as such, likely to be an under-estimate of true CNV at the kallikrein locus [23] .
It was surmised that CNV of the MSR1 element might cause over-expression of KLK14 in BrCa. Reporter assay showed that presence of the 3 0 UTR MSR1 cluster acted as an enhancer element. Critically, in vitro, the 9-copy allele induces a greater enhancement of transcription than the 11-copy allele. This was consistently demonstrated in three different cell lines-including MCF7, which is a BrCa cell line. If the same phenomenon occurred in vivo, it strongly suggests that the 9-copy allele induces higher levels of KLK14 gene expression as compared with the 11-copy allele. It was postulated, therefore, that the 9-copy allele might be associated with higher risk of BrCa.
In our case-control cohort, it was shown that the 9-copy allele was associated with a significantly increased risk of disease. Increasing presence of the 9-copy allele was associated with a greater risk of BrCa: thus, as compared with 11-copy Table 2 . Univariate binary logistic regression for the three most common genotypes of the MSR1 cluster located in the 3 0 UTR of KLK14 in either heterozygous (9, 11 genotype) or homozygous form (9, 9 genotype), as compared with the major allele homozygotes (11, 11 homozygotes, the heterozygous carriers of the 9-copy allele had an OR of 1.2 and, of greater influence, those homozygous for the 9-copy allele had an OR of 3.5. This effect was even greater in those with early-onset disease, with a remarkably high effect (1.7 to 5.3-fold increased risk). Furthermore, it seems the risk (9-copy) allele is strongly associated with the ER positive histological subtype, but not the ER negative subtype.
In an association study, it is critical to show reproducibility in a second population. Here, we were able to re-analyse previously published data from a small cohort from Toronto, Canada [19] . Our analysis confirmed a statistically significant association between the 9-copy allele and risk of non-familial BrCa. Given the small n, however, caution would be advised in interpretation of the ORs generated from this analysis.
As high-penetrance alleles are mainly associated with familial forms of cancer, it is to be expected that a study of non-familial BrCa would display an allele with low-or moderate-penetrance cancer susceptibility. It is crucial to note, however, that with an OR of 1.2-3.5 (1.7-5.3 in early-onset disease), the KLK14-MSR1 cluster is by far the most influential susceptibility allele identified to date in non-familial BrCa. Crucially, even the identification of this single risk allele with such a high influence is a major step towards stratification of risk of non-familial BrCa in women in the general population, as even this one locus could be clinically useful for a predictive test. However, it is predicted that study of other kallikreins and MSR1-containing loci would allow formulation of an even more powerful method for risk stratification in non-familial BrCa-this facilitating enrolment into effective screening and early prevention programmes for those at highest risk.
To further confirm the association of MSR1 CNV with malignancy, a case-control analysis was carried out between the KLK14-MSR1 cluster and prostate cancer. This confirmed that the higher expressing, 9-copy allele was a robust and significant risk factor for prostate cancer in the population studied. The 9-copy allele was associated with prostate cancer risk at allele level (OR ¼ 1.3; P ¼0.001) and genotype level (OR ¼ 1.3; P ¼0.001), these results being age-independent and confirmed by bootstrapping. Furthermore, the major 11-copy allele was associated with a significant protective effect (OR ¼ 0.65; P ¼0.025).
The association between the KLK14 higher expressing allele and risk of prostate cancer makes logical sense, as KLK14 expression is significantly higher in cancerous compared with non-cancerous prostatic tissue [24] . Furthermore, up-regulation of KLK14 is observed in advanced and more aggressive tumours, and has been associated with disease progression [24, 25] .
It would be valuable to assess genotype of all MSR1 clusters across the kallikrein locus in a case-control cohort of patients with breast, prostate and other endocrine-related malignancies. Subsequently, MSR1 elements outside the kallikrein locus could be studied, in malignancy and other diseases associated with these genes. Furthermore, we predict that hypermutation of the MSR1 clusters might occur within tumour cells, propagating further gene dysregulation. Finally, protease inhibitors are an emerging class of chemotherapeutic agents and, accordingly, pharmaceutical targeting of MSR1 might represent a new anticancer chemotherapeutic approach.
Conclusion
In summary, this study provides persuasive evidence that MSR1 repeats are global regulators of gene expression and that this prototypical 'junk DNA' element can influence many important human diseases. We anticipate that study of MSR1 will allow development of tools for screening, diagnosis and prognostication for many diseases, and hope that long-term this will allow early intervention to predict and prevent devastating diseases, such as breast, prostate and other cancers.
